Treatment for mitochondrial diseases

Citations Over TimeTop 18% of 2020 papers

Abstract

Mitochondrial diseases are predominantly caused by mutations of mitochondrial or nuclear DNA, resulting in multisystem defects. Current treatments are largely supportive, and the disorders progress relentlessly. Nutritional supplements, pharmacological agents and physical therapies have been used in different clinical trials, but the efficacy of these interventions need to be further evaluated. Several recent reviews discussed some of the interventions but ignored bias in those trials. This review was conducted to discover new studies and grade the original studies for potential bias with revised Cochrane Collaboration guidelines. We focused on seven published studies and three unpublished studies; eight of these studies showed improvement in outcome measurements. In particular, two of the interventions have been tested in studies with strict design, which we believe deserve further clinical trials with a large sample. Additionally, allotopic expression of the ND4 subunit seemed to be an effective new treatment for patients with Leber hereditary optic neuropathy.

Related Papers

• → Measurement of ATP production in mitochondrial disorders(2006)37 cited
• → Large Mitochondrial DNA Deletion in an Infant with Addison Disease(2011)13 cited
• → Comprehensive Molecular Diagnosis of Mitochondrial Disorders: Qualitative and Quantitative Approach(2004)20 cited
• → [Characteristics of molecular genetics and research progress on mitochondrial diseases].(2016)1 cited
• → Genome editing to treat mitochondrial DNA disorders(2015)